Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 35/100

Failure Rate

0.0%

0 terminated/withdrawn out of 5 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

67%

2 of 3 completed trials have results

Key Signals

2 recruiting2 with results

Enrollment Performance

Analytics

Phase 2
2(66.7%)
Phase 1
1(33.3%)
3Total
Phase 2(2)
Phase 1(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (5)

Showing 5 of 5 trials
NCT06346106Recruiting

The Diagnostic Experience of Male Rett Syndrome

Role: collaborator

NCT05432349Recruiting

Rett Syndrome Registry

Role: lead

NCT01777542Phase 2Completed

Treatment of Rett Syndrome With Recombinant Human IGF-1

Role: collaborator

NCT01703533Phase 2Completed

A Safety Study of NNZ-2566 in Patients With Rett Syndrome

Role: collaborator

NCT01253317Phase 1Completed

Treatment of Rett Syndrome With rhIGF-1 (Mecasermin [rDNA]Injection)

Role: collaborator

All 5 trials loaded